Executives at Genmab are confident that the firm has an edge over Roche in the new class of CD20xCD3 bispecific antibody lymphoma therapies, although it could still be beaten to the US market by their rivals.
Any advantage in terms of data will be important to Genmab and its partner AbbVie, in what is expected...